Progressive Care (RXMD) 10-Q 15 May 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 10, 2024
Document Information [Line Items]
Entity Central Index Key	0001402945
Entity Registrant Name	Progressive Care Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	000-52684
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0186005
Entity Address, Address Line One	400 Ansin Blvd., Suite A
Entity Address, City or Town	Hallandale Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33009
City Area Code	305
Local Phone Number	760-2053
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,240,731

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash	$ 5,544	$ 7,895
Accounts receivable – trade, net	12,253	8,339
Receivables - other, net	2,068	1,846
Inventory, net	3,385	3,069
Prepaid expenses	185	334
Total Current Assets	23,435	21,483
Property and equipment, net	3,220	3,284
Other Assets
Goodwill	731	731
Intangible assets, net	13,706	14,398
Operating right-of-use assets, net	249	427
Finance right-of-use assets, net	18	22
Deposits	39	39
Total Other Assets	14,743	15,617
Total Assets	41,398	40,384
Current Liabilities
Accounts payable and accrued liabilities	13,555	12,158
Notes payable	144	145
Operating lease liabilities	159	170
Finance lease liabilities	20	18
Total Current Liabilities	13,878	12,491
Long-term Liabilities
Notes payable, net of current portion	1,081	1,110
Operating lease liabilities, net of current portion	182	214
Finance lease liabilities, net of current portion	0	5
Total Liabilities	15,141	13,820
Commitments and Contingencies
Stockholders’ Equity
Common stock ($0.0001 par value, 100,000,000 shares authorized; 6,240,731 and 6,222,781 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively)	67	67
Additional paid-in capital	60,951	60,886
Accumulated deficit	(34,761)	(34,389)
Total Stockholders’ Equity	26,257	26,564
Total Liabilities and Stockholders’ Equity	41,398	40,384
Series A Preferred Stock [Member]
Stockholders’ Equity
Preferred Stock	0	0
Series B Preferred Stock [Member]
Stockholders’ Equity
Preferred Stock	$ 0	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, shares authorized (in shares)	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	6,240,731	6,222,781
Common stock, shares outstanding (in shares)	6,240,731	6,222,781
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	51	51
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	100,000	100,000
Preferred stock, shares issued (in shares)	3,000	3,000
Preferred stock, shares outstanding (in shares)	3,000	3,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024		Mar. 31, 2023
Revenues, net	$ 14,628		$ 11,392
Costs of revenue	10,623		8,245
Gross profit	4,005		3,147
Operating expenses
Salaries and wages	2,116		1,598
Professional fees	478		774
Depreciation and amortization	776		64
Selling, general, and administrative	900		697
Impairment loss	132	[1]	0
Total operating expenses	4,402		3,133
(Loss) income from operations	(397)		14
Other income (expense):
Gain on sale or disposal of property and equipment	1		0
Interest income	40		6
Interest expense	(16)		(150)
Total other income (expense)	25		(144)
Loss before income taxes	(372)		(130)
Provision for income taxes	0		0
Net loss attributable to common shareholders	$ (372)		$ (130)
Basic and diluted weighted average loss per common share (in dollars per share)	$ (0.06)		$ (0.04)
Weighted average number of common shares outstanding during the period – basic and diluted (in shares)	6,240		3,356
Product [Member]
Revenues, net	$ 11,255		$ 9,794
Costs of revenue	10,560		8,196
Service [Member]
Revenues, net	3,373		1,598
Costs of revenue	$ 63		$ 49
[1]Pharmacy Operations impairment losses during the three months ended March 31, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	0	3	3,347
Balance at Dec. 31, 2022	$ 0	$ 0	$ 67	$ 22,525	$ (14,974)	$ 7,618
Stock-based compensation (in shares)	0	0	11
Stock-based compensation	$ 0	$ 0	$ 0	50	0	50
Net loss for the three months ended March 31, 2024	$ 0	$ 0	$ 0	0	(130)	(130)
Balance (in shares) at Mar. 31, 2023	0	3	3,358
Balance at Mar. 31, 2023	$ 0	$ 0	$ 67	22,575	(15,104)	7,538
Balance (in shares) at Dec. 31, 2023	0	3	6,223
Balance at Dec. 31, 2023	$ 0	$ 0	$ 67	60,886	(34,389)	26,564
Stock-based compensation (in shares)	0	0	18
Stock-based compensation	$ 0	$ 0	$ 0	65	0	65
Net loss for the three months ended March 31, 2024	$ 0	$ 0	$ 0	0	(372)	(372)
Balance (in shares) at Mar. 31, 2024	0	3	6,241
Balance at Mar. 31, 2024	$ 0	$ 0	$ 67	$ 60,951	$ (34,761)	$ 26,257

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024		Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (372)		$ (130)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation	79		44
Change in provision for doubtful accounts	2		9
Amortization of debt issuance costs and debt discounts	0		96
Stock-based compensation	65		60
Amortization of right-of-use assets - finance leases	5		8
Amortization of right-of-use assets - operating leases	44		36
Change in accrued interest on notes payable	0		34
Amortization of intangible assets	692		12
Gain on sale or disposal of property and equipment	(1)		0
Impairment loss	132	[1]	0
Changes in operating assets and liabilities:
Accounts receivable	(4,138)		(378)
Grant receivable	0		(277)
Inventory	(316)		(550)
Prepaid expenses	149		19
Deposits	0		(1)
Accounts payable and accrued liabilities	1,423		1,885
Operating lease liabilities	(41)		(40)
Net cash (used in) provided by operating activities	(2,277)		827
Cash flows from investing activities:
Purchase of property and equipment	(24)		(17)
Proceeds from sale or disposal of property and equipment	1		0
Net cash used in investing activities	(23)		(17)
Cash flows from financing activities:
Payments on notes payable	(46)		(91)
Payments on finance lease liabilities	(5)		(10)
Net cash used in financing activities	(51)		(101)
(Decrease) increase in cash	(2,351)		709
Cash at beginning of period	7,895		6,743
Cash at end of period	5,544		7,452
Supplemental disclosures of cash flow information:
Cash paid for interest	16		19
Cash paid for income taxes	$ 0		$ 0
[1]Pharmacy Operations impairment losses during the three months ended March 31, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Note 1 - Organization & Nature

Note 1 - Organization & Nature of Operations	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Nature of Operations [Text Block]	Note 1. Progressive Care Inc. (“Progressive”) was incorporated under the laws of the state of Delaware on October 31, 2006. Progressive, through its wholly-owned subsidiaries, Pharmco, LLC (“Pharmco 901” 1002, 1002” 1103 1204 1103” 1204” Pharmco 901 November 29, 2005 901 October 21, 2010. 901 not Pharmco 1103 1103 June 1, 2019. Pharmco 1002 1002 July 1, 2018. ClearMetrX was formed on June 10, 2020 third 340B RXMD Therapeutics was formed on October 1, 2019. no We have organized our operations into two 15. On June 30, 2023, July 1, 2023, 805, Business Combinations July 1, 2023 June 30, 2023 July 1, 2023

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation and Principles of Consolidation	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Basis of Accounting [Text Block]	Note 2. The accompanying Unaudited Condensed Consolidated Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) on a basis consistent with reporting interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. The year-end balance sheet data presented for comparative purposes was derived from audited consolidated financial statements. Interim results are not may not 2023 10 The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation. Certain 2023 2024 not three March 31, 2023.

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3. The significant accounting policies of the Company were described in Note 3 10 December 31, 2023 no three March 31, 2024 Cash The Company maintains its cash in bank deposit accounts at several financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) and at times may $250,000. March 31, 2024 July 2023, $250,000. Concentrations Suppliers: The Company had significant concentrations with one vendor. The purchases from this significant vendor were 98% and 96% of total vendor purchases for the three March 31, 2024 three March 31, 2023 Customers: The Company derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three Successor Predecessor Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 A 33 % — B 21 % 1 % C 16 % 53 % Direct and Indirect Remuneration (“DIR”) Fees DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three January – April 20xx July – August 20xx December 31, 2023, not second 2024. may January 1, 2024, Recently Adopted Accounting Standards None. Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Subsequent Events Merger Agreement On April 12, 2024, The Merger Agreement and the transactions contemplated thereby were negotiated and approved by a Special Committee comprised of three not Lock-Up Agreements On April 9, 2024,

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Accounting standards define fair value as the price that would be received from selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards establish a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value and also establishes the following three may Level 1: Level 2: 1 not Level 3: no The following methods and assumptions were used by the Company in estimating fair value disclosures for financial instruments: ● Cash, accounts receivable, and accounts payable and accrued liabilities: ● Notes payable and lease liabilities: 2 Fair Value Measurement on a Nonrecurring Basis Common Stock Purchase Warrants As of March 31, 2024, 3 3.7%; 102%; 13.

Note 5 - Revenue

Note 5 - Revenue	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 5. The following table disaggregates net revenues by categories (in thousands): Successor Predecessor Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 Sales of products, net Prescription revenue, net of PBM fees $ 11,324 $ 9,771 COVID-19 testing revenue — 45 Subtotal 11,324 9,816 Revenues from services: 340B contract revenue 3,304 1,576 Revenues, net $ 14,628 $ 11,392

Note 6 - Earnings (Loss) Per Sh

Note 6 - Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 6. Basic earnings per share is computed by dividing net (loss) income available to common shareholders by the weighted average number of common shares outstanding during the year, excluding the effects of any potentially dilutive securities. Diluted earnings per share gives effect to all potentially dilutive shares of common stock outstanding during the year including common stock purchase warrants and stock options, using the treasury stock method, and convertible debt, using the if converted method. Diluted earnings per share excludes all dilutive potential of shares of common stock if their effect is anti-dilutive. The components of basic and diluted EPS were as follows (in thousands, except per share data). For all periods presented, the Company incurred a net loss causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in diluted loss per common share and basic loss per common share being equivalent. Successor Predecessor Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 Net loss attributable to common shareholders $ (372 ) $ (130 ) Basic weighted average common shares outstanding 6,240 3,356 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 6,240 3,356 Basic weighted average loss per common share $ (0.06 ) $ (0.04 ) Diluted weighted average loss per common share $ (0.06 ) $ (0.04 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Common stock purchase warrants 102,468 60,152 Stock options 59,623 151,937 162,091 212,089

Note 7 - Accounts Receivable -

Note 7 - Accounts Receivable - Trade, Net	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 7. Trade, net Accounts receivable consisted of the following (in thousands): Successor March 31, 2024 December 31, 2023 Gross accounts receivable – trade $ 12,527 $ 8,611 Less: allowance for credit losses (274 ) (272 ) Accounts receivable – trade, net $ 12,253 $ 8,339 The Successor Company increased the allowance for credit losses in the amount of approximately $2,000 for the three March 31, 2024 three March 31, 2023. Accounts receivable – trade, net for the Predecessor Company as of January 1, 2023 March 31, 2023

Note 8 - Receivables - Other, n

Note 8 - Receivables - Other, net	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	Note 8. Receivables – Other, net consisted of the following (in thousands): Successor March 31, 2024 December 31, 2023 Performance bonuses $ 1,859 $ 1,602 Customers 179 192 Other 30 52 $ 2,068 $ 1,846 Performance bonuses, paid annually by PBMs, are estimated based on historical pharmacy performance and prior payments received. Other receivables are loans to employees.

Note 9 - Property and Equipment

Note 9 - Property and Equipment, Net	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 9. Property and equipment, net consisted of the following (in thousands): Successor Estimated Useful Life March 31, 2024 December 31, 2023 Building 40 years $ 2,116 $ 2,116 Vehicles 3 - 5 years 585 595 Furniture and equipment 5 years 388 388 Land --- 184 184 Leasehold improvements and fixtures Lesser of estimated useful life or life of lease 119 76 Computer equipment 3 years 39 39 Construction in progress --- — 22 Total 3,431 3,420 Less: accumulated depreciation (211 ) (136 ) Property and equipment, net $ 3,220 $ 3,284 Depreciation expense for the Successor Company was approximately $79,000 for the three March 31, 2024 three March 31, 2023

Note 10 - Goodwill and Intangib

Note 10 - Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 10. Goodwill Goodwill was approximately $0.7 million as of March 31, 2024 December 31, 2023 ( no three March 31, 2024. Intangible Assets Intangible assets consisted of the following (in thousands): Successor March 31, 2024 December 31, 2023 Gross amount Accumulated amortization Net Amount Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (1,219 ) $ 6,911 $ 8,130 $ (807 ) $ 7,323 Tradenames 4,700 (353 ) 4,347 4,700 (224 ) 4,476 Developed technology 2,880 (432 ) 2,448 2,880 (281 ) 2,599 Total intangible assets $ 15,710 $ (2,004 ) $ 13,706 $ 15,710 $ (1,312 ) $ 14,398 Amortization of intangible assets for the Successor Company was approximately $0.7 million for the three March 31, 2024. three March 31, 2023. The following table represents the total estimated future amortization of intangible assets for the five March 31, 2024 ( Successor Year Amount 2024 (remaining nine months) $ 2,004 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 13,706

Note 11 - Accounts Payable and

Note 11 - Accounts Payable and Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 11. Accounts payable and accrued liabilities consisted of the following (in thousands): Successor March 31, 2024 December 31, 2023 Accounts payable – trade $ 12,752 $ 11,256 Accrued payroll and payroll taxes 356 167 Accrued PBM fees 366 571 Other accrued liabilities 81 164 Total $ 13,555 $ 12,158

Note 12 - Notes Payable

Note 12 - Notes Payable	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 12. Notes payable consisted of the following (in thousands): Successor March 31, 2024 December 31, 2023 A. Mortgage note payable - commercial bank - collateralized $ 1,118 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 82 90 Subtotal 1,225 1,255 Less: current portion of notes payable (144 ) (145 ) Long-term portion of notes payable $ 1,081 $ 1,110 The corresponding notes payable above are more fully discussed below: (A) Mortgage Note Payable – collateralized In 2018, 901 400 December 14, 2028 119 January 2019, not December 14, 2028. (B) Note Payable – Uncollateralized As of March 31, 2024 December 31, 2023 (C) Notes Payable – Collateralized In April 2021, September 2021, 46 March 31, 2024 December 31, 2023 In July 2022, 60 January 2023. March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023, In September 2022, 24 October 2022. March 31, 2024 December 31, 2023 March 31, 2024 December 31, 2023, Principal outstanding as of March 31, 2024 Successor Year Amount 2024 (remaining nine months) $ 115 2025 114 2026 119 2027 124 2028 753 Total $ 1,225 Interest expense on these notes payable for the Successor Company was approximately $16,000 for the three March 31, 2024. three March 31, 2023.

Note 13 - Stockholders' Equity

Note 13 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Equity [Text Block]	Note 13. Equity Preferred Stock The Company has 10,000,000 shares of preferred stock authorized. As of March 31, 2024 December 31, 2023, Series A Preferred Stock - Predecessor Company The Series A preferred stock is a non-dividend producing instrument that ranks superior to the Company’s common stock. Each one 1 x 0.019607 multiplied by divided by 0.49, minus With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Series A Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws. In July 2014, October 2020, August 2022, Series B Convertible Preferred Stock - Predecessor Company On August 30, 2022, one one may The Series B Convertible Preferred Stock ranks senior to our common stock as to distribution of assets upon liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary. The shares of Series B Convertible Preferred Stock shall have a liquidation preference to all other classes of stock of the Company in the amount of $2,000 per share. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series B Convertible Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company (i) $2,000 per share plus (ii) the same amount that a holder of common stock would receive if the Series B Convertible Preferred Stock were fully converted to common stock which amounts shall be paid pari passu With respect to all matters upon which stockholders are entitled to vote or to which shareholders are entitled to give consent, the holders of the outstanding shares of Preferred Stock shall vote together with the holders of common stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws. Common Stock and Common Stock Purchase Warrants On May 5, 2023, three 480 July 1, 2023, Also on May 5, 2023, September 2, 2022, three 480 July 1, 2023, March 31, 2024, At the same time as the SPA and DCA, the Predecessor Company and NextPlat entered into the Debenture Purchase Agreement. Under the Debenture Purchase Agreement, the Predecessor Company agreed to issue, and NextPlat agreed to purchase, from time to time during the three March 31, 2024, Dawson James Securities, Inc. (the “Placement Agent”) served as placement agent for the Unit Purchase. In consideration for the Placement Agent’s services, the Predecessor Company issued to the Placement Agent and its affiliates warrants to purchase 91,000 shares of Common Stock (the “Placement Agent Warrants”). The Placement Agent Warrants have a five December 2023. 480 In addition, the Predecessor Company issued 330,000 warrants to certain existing Progressive Care investors to induce them to approve the transaction contemplated by the SPA (the “Inducement Warrants”). Charles M. Fernandez and Rodney Barreto received Inducement Warrants to purchase 190,000 and 30,000 shares of Common Stock, respectively. The Inducement Warrants have a three 480 July 1, 2023, March 31, 2024,

Note 14 - Stock-based Compensat

Note 14 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 14. Stock-based compensation is recorded in selling, general, and administrative expenses in the Unaudited Condensed Consolidated Statement of Operations. The Successor Company recorded total stock-based compensation expense of approximately $65,000 for the three March 31, 2024. three March 31, 2023.

Note 15 - Reportable Segments

Note 15 - Reportable Segments	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 15. The Company has two 19 340B 340B Corporate includes certain assets and expenses related to corporate functions that are not The Company evaluates the performance of each of the segments based on income (loss) from operations. While the Company believes there are synergies between the two The accounting policies used to determine the results of the operating segments are the same as those utilized for the Consolidated Financial Statements as a whole. There are no The following tables present a summary of net income (loss) of the reportable segments (in thousands): Successor Three Months Ended March 31, 2024 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 11,255 $ — $ — $ 11,255 Revenues from services 2,840 533 — 3,373 Revenues, net 14,095 533 — 14,628 Costs of products 10,560 — — 10,560 Costs of services — 63 — 63 Costs of revenue 10,560 63 — 10,623 Gross profit 3,535 470 — 4,005 Operating expenses: Salaries and wages 1,901 33 182 2,116 Professional fees 4 81 393 478 Depreciation and amortization 615 156 5 776 Selling, general, and administrative 770 7 123 900 Impairment loss (1) 132 — — 132 Total operating expenses 3,422 277 703 4,402 Income (loss) from operations 113 193 (703 ) (397 ) Other (expense) income (14 ) — 39 25 Income (loss) before income taxes 99 193 (664 ) (372 ) Provision for income taxes — — — — Net income (loss) $ 99 $ 193 $ (664 ) $ (372 ) ( 1 three March 31, 2024 not Predecessor Three Months Ended March 31, 2023 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 9,794 $ — $ — $ 9,794 Revenues from services 1,081 517 — 1,598 Revenues, net 10,875 517 — 11,392 Costs of products 8,196 — — 8,196 Costs of services — 49 — 49 Costs of revenue 8,196 49 — 8,245 Gross profit 2,679 468 — 3,147 Operating expenses: Salaries and wages 1,445 33 120 1,598 Professional fees 383 96 295 774 Depreciation and amortization 60 4 — 64 Selling, general, and administrative 588 4 105 697 Total operating expenses 2,476 137 520 3,133 Income (loss) from operations 203 331 (520 ) 14 Other expense (13 ) — (132 ) (144 ) Income (loss) before income taxes 190 331 (652 ) (130 ) Provision for income taxes — — — — Net income (loss) $ 190 $ 331 $ (652 ) $ (130 ) Pharmacy Operations Third-Party Administration Corporate Eliminations (1) Total Consolidated Total Assets as of March 31, 2024 (Successor) $ 39,439 $ 4,733 $ — $ (2,774 ) $ 41,398 Total Assets as of December 31, 2023 (Successor) $ 38,516 $ 4,573 $ 69 $ (2,774 ) $ 40,384 ( 1 Capital expenditures for the Pharmacy Operations reporting segment were approximately $0.1 million for the three March 31, 2024 three March 31, 2023 no three March 31, 2024 three March 31, 2023

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 16. Successor Company During the three March 31, 2024, May 1, 2023. Predecessor Company On February 1, 2023, May 1, 2023, three March 31, 2023,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	5. OTHER INFORMATION Rule 10b5 1 During the three March 31, 2024 no 10b5 1 10b5 1 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company maintains its cash in bank deposit accounts at several financial institutions, which are insured by the Federal Deposit Insurance Corporation (“FDIC”) and at times may $250,000. March 31, 2024 July 2023, $250,000.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations Suppliers: The Company had significant concentrations with one vendor. The purchases from this significant vendor were 98% and 96% of total vendor purchases for the three March 31, 2024 three March 31, 2023 Customers: The Company derives a significant portion of sales from prescription drug sales reimbursed through prescription drug plans administered by pharmacy benefit managers (“PBM”) companies. Prescription reimbursements from our three Successor Predecessor Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 A 33 % — B 21 % 1 % C 16 % 53 %
Renumeration Fees [Policy Text Block]	Direct and Indirect Remuneration (“DIR”) Fees DIR fees are fees charged by PBMs to pharmacies for network participation as well as periodic reimbursement reconciliations. The Company accrues an estimate of PBM fees, including DIR fees, which are assessed or expected to be assessed by payers at some point after adjudication of a claim, as a reduction of prescription revenue at the time revenue is recognized. Changes in the estimate of such fees are recorded as an adjustment to revenue when the change becomes known. Through December 31, 2023, not two two three January – April 20xx July – August 20xx December 31, 2023, not second 2024. may January 1, 2024,
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards None. Accounting Pronouncements Issued but not In November 2023, 2023 07, 280 2023 07” 2023 07 December 15, 2023, December 15, 2024, Q1 2025, December 31, 2024. not In December 2023, 2023 09, 740 2023 09” 2023 09 December 15, 2024, January 1, 2025. not Subsequent Events Merger Agreement On April 12, 2024, The Merger Agreement and the transactions contemplated thereby were negotiated and approved by a Special Committee comprised of three not Lock-Up Agreements On April 9, 2024,

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Successor Predecessor Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 A 33 % — B 21 % 1 % C 16 % 53 %

Note 5 - Revenue (Tables)

Note 5 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Successor Predecessor Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 Sales of products, net Prescription revenue, net of PBM fees $ 11,324 $ 9,771 COVID-19 testing revenue — 45 Subtotal 11,324 9,816 Revenues from services: 340B contract revenue 3,304 1,576 Revenues, net $ 14,628 $ 11,392

Note 6 - Earnings (Loss) Per _2

Note 6 - Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Successor Predecessor Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 Net loss attributable to common shareholders $ (372 ) $ (130 ) Basic weighted average common shares outstanding 6,240 3,356 Potentially dilutive common shares — — Diluted weighted average common shares outstanding 6,240 3,356 Basic weighted average loss per common share $ (0.06 ) $ (0.04 ) Diluted weighted average loss per common share $ (0.06 ) $ (0.04 ) Potentially dilutive common shares excluded from the calculation of diluted weighted average loss per common share: Common stock purchase warrants 102,468 60,152 Stock options 59,623 151,937 162,091 212,089

Note 7 - Accounts Receivable _2

Note 7 - Accounts Receivable - Trade, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Successor March 31, 2024 December 31, 2023 Gross accounts receivable – trade $ 12,527 $ 8,611 Less: allowance for credit losses (274 ) (272 ) Accounts receivable – trade, net $ 12,253 $ 8,339

Note 8 - Receivables - Other,_2

Note 8 - Receivables - Other, net (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Other Receivables, Net [Table Text Block]	Successor March 31, 2024 December 31, 2023 Performance bonuses $ 1,859 $ 1,602 Customers 179 192 Other 30 52 $ 2,068 $ 1,846

Note 9 - Property and Equipme_2

Note 9 - Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	Successor Estimated Useful Life March 31, 2024 December 31, 2023 Building 40 years $ 2,116 $ 2,116 Vehicles 3 - 5 years 585 595 Furniture and equipment 5 years 388 388 Land --- 184 184 Leasehold improvements and fixtures Lesser of estimated useful life or life of lease 119 76 Computer equipment 3 years 39 39 Construction in progress --- — 22 Total 3,431 3,420 Less: accumulated depreciation (211 ) (136 ) Property and equipment, net $ 3,220 $ 3,284

Note 10 - Goodwill and Intang_2

Note 10 - Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Successor March 31, 2024 December 31, 2023 Gross amount Accumulated amortization Net Amount Gross amount Accumulated amortization Net Amount Pharmacy records $ 8,130 $ (1,219 ) $ 6,911 $ 8,130 $ (807 ) $ 7,323 Tradenames 4,700 (353 ) 4,347 4,700 (224 ) 4,476 Developed technology 2,880 (432 ) 2,448 2,880 (281 ) 2,599 Total intangible assets $ 15,710 $ (2,004 ) $ 13,706 $ 15,710 $ (1,312 ) $ 14,398
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Successor Year Amount 2024 (remaining nine months) $ 2,004 2025 2,672 2026 2,672 2027 2,672 2028 1,571 Thereafter 2,115 Total $ 13,706

Note 11 - Accounts Payable an_2

Note 11 - Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Successor March 31, 2024 December 31, 2023 Accounts payable – trade $ 12,752 $ 11,256 Accrued payroll and payroll taxes 356 167 Accrued PBM fees 366 571 Other accrued liabilities 81 164 Total $ 13,555 $ 12,158

Note 12 - Notes Payable (Tables

Note 12 - Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Debt [Table Text Block]	Successor March 31, 2024 December 31, 2023 A. Mortgage note payable - commercial bank - collateralized $ 1,118 $ 1,140 B. Note payable - uncollateralized 25 25 C. Notes payable - collateralized 82 90 Subtotal 1,225 1,255 Less: current portion of notes payable (144 ) (145 ) Long-term portion of notes payable $ 1,081 $ 1,110
Schedule of Maturities of Long-Term Debt [Table Text Block]	Successor Year Amount 2024 (remaining nine months) $ 115 2025 114 2026 119 2027 124 2028 753 Total $ 1,225

Note 15 - Reportable Segments (

Note 15 - Reportable Segments (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Successor Three Months Ended March 31, 2024 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 11,255 $ — $ — $ 11,255 Revenues from services 2,840 533 — 3,373 Revenues, net 14,095 533 — 14,628 Costs of products 10,560 — — 10,560 Costs of services — 63 — 63 Costs of revenue 10,560 63 — 10,623 Gross profit 3,535 470 — 4,005 Operating expenses: Salaries and wages 1,901 33 182 2,116 Professional fees 4 81 393 478 Depreciation and amortization 615 156 5 776 Selling, general, and administrative 770 7 123 900 Impairment loss (1) 132 — — 132 Total operating expenses 3,422 277 703 4,402 Income (loss) from operations 113 193 (703 ) (397 ) Other (expense) income (14 ) — 39 25 Income (loss) before income taxes 99 193 (664 ) (372 ) Provision for income taxes — — — — Net income (loss) $ 99 $ 193 $ (664 ) $ (372 ) Predecessor Three Months Ended March 31, 2023 Pharmacy Operations Third-Party Administration Corporate Total Consolidated Sales of products, net $ 9,794 $ — $ — $ 9,794 Revenues from services 1,081 517 — 1,598 Revenues, net 10,875 517 — 11,392 Costs of products 8,196 — — 8,196 Costs of services — 49 — 49 Costs of revenue 8,196 49 — 8,245 Gross profit 2,679 468 — 3,147 Operating expenses: Salaries and wages 1,445 33 120 1,598 Professional fees 383 96 295 774 Depreciation and amortization 60 4 — 64 Selling, general, and administrative 588 4 105 697 Total operating expenses 2,476 137 520 3,133 Income (loss) from operations 203 331 (520 ) 14 Other expense (13 ) — (132 ) (144 ) Income (loss) before income taxes 190 331 (652 ) (130 ) Provision for income taxes — — — — Net income (loss) $ 190 $ 331 $ (652 ) $ (130 )
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Pharmacy Operations Third-Party Administration Corporate Eliminations (1) Total Consolidated Total Assets as of March 31, 2024 (Successor) $ 39,439 $ 4,733 $ — $ (2,774 ) $ 41,398 Total Assets as of December 31, 2023 (Successor) $ 38,516 $ 4,573 $ 69 $ (2,774 ) $ 40,384

Note 1 - Organization & Natur_2

Note 1 - Organization & Nature of Operations (Details Textual)		3 Months Ended
	Jul. 01, 2023 shares	Mar. 31, 2024	Oct. 21, 2010
Number of Reportable Segments		2
NextPlat Corp. and Messrs [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	632,269
Fernandez [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	211,470
Barreto [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	130,571
NextPlat, Chief Executive Officer, and Board Director [Member]
Ownership Percentage	53%
Pharmco LLC [Member]
Subsidiary, Ownership Percentage, Parent			100%

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023
Cash, Uninsured Amount	$ 0.5
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member]
Number of Major Vendors	1	1
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member] | One Vendor [Member]
Concentration Risk, Percentage	98%	96%

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Trade, Net - Concentrations (Details) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pharmacy Benefit Managers A [Member]
Concentration	33%	0%
Pharmacy Benefit Managers B [Member]
Concentration	21%	1%
Pharmacy Benefit Managers C [Member]
Concentration	16%	53%

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Details Textual) - Common Stock Purchase Warrants [Member] $ / shares in Units, $ in Millions	Mar. 31, 2024 USD ($) $ / shares
Warrants and Rights Outstanding | $	$ 4.6
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 2.2
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.035
Minimum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	3
Minimum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.93
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.037
Maximum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.6
Maximum [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.02

Note 5 - Revenue - Disaggregati

Note 5 - Revenue - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 14,628	$ 11,392
Prescription [Member]
Revenue	11,324	9,771
COVID-19 Testing [Member]
Revenue	0	45
Product [Member]
Revenue	11,324	9,816
Three Hundred Forty B Contract [Member]
Revenue	$ 3,304	$ 1,576

Note 6 - Earnings (Loss) Per _3

Note 6 - Earnings (Loss) Per Share - Components of Basic and Dilutes Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net loss attributable to common shareholders	$ (372)	$ (130)
Weighted average number of common shares outstanding during the period – basic and diluted (in shares)	6,240	3,356
Potentially dilutive common shares (in shares)	0	0
Diluted weighted average common shares outstanding (in shares)	6,240	3,356
Basic and diluted weighted average loss per common share (in dollars per share)	$ (0.06)	$ (0.04)
Diluted weighted average loss per common share (in dollars per share)	$ (0.06)	$ (0.04)
Antidilutive securities (in shares)	162,091	212,089
Warrant [Member]
Antidilutive securities (in shares)	102,468	60,152
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	59,623	151,937

Note 7 - Accounts Receivable _3

Note 7 - Accounts Receivable - Trade, Net (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jan. 01, 2023
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,000	$ 9,000
Accounts Receivable, after Allowance for Credit Loss		4,300,000	$ 3,400,000
Provision Approximation [Member]
Accounts Receivable, Credit Loss Expense (Reversal)	$ 2,000	$ 9,000

Note 7 - Accounts Receivable _4

Note 7 - Accounts Receivable - Trade, Net - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Gross accounts receivable – trade	$ 12,527	$ 8,611
Less: allowance for credit losses	(274)	(272)
Accounts receivable – trade, net	$ 12,253	$ 8,339

Note 8 - Receivables - Other,_3

Note 8 - Receivables - Other, Net - Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Performance bonuses	$ 1,859	$ 1,602
Customers	179	192
Other	30	52
Other Receivables, Net, Current	$ 2,068	$ 1,846

Note 9 - Property and Equipme_3

Note 9 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Depreciation	$ 79,000	$ 44,000
Depreciation Approximation [Member]
Depreciation	$ 79,000	$ 44,000

Note 9 - Property and Equipme_4

Note 9 - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property and equipment, gross	$ 3,431	$ 3,420
Less: accumulated depreciation	(211)	(136)
Property and equipment, net	$ 3,220	3,284
Building [Member]
Property, Plant and Equipment, Useful Life (Year)	40 years
Property and equipment, gross	$ 2,116	2,116
Vehicles [Member]
Property and equipment, gross	$ 585	595
Vehicles [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Vehicles [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Property and equipment, gross	$ 388	388
Land [Member]
Property and equipment, gross	184	184
Leasehold Improvements [Member]
Property and equipment, gross	$ 119	76
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Property and equipment, gross	$ 39	39
Construction in Progress [Member]
Property and equipment, gross	$ 0	$ 22

Note 10 - Goodwill and Intang_3

Note 10 - Goodwill and Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Goodwill	$ 731,000		$ 731,000
Amortization of Intangible Assets	692,000	$ 12,000
Amortization Approximation [Member]
Amortization of Intangible Assets	700,000	$ 12,000
TPA Reporting Segment [Member]
Goodwill	$ 700,000		$ 700,000

Note 10 - Goodwill and Intang_4

Note 10 - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Gross intangible assets	$ 15,710	$ 15,710
Accumulated amortization	(2,004)	(1,312)
Net intangible assets	13,706	14,398
Pharmacy Records [Member]
Gross intangible assets	8,130	8,130
Accumulated amortization	(1,219)	(807)
Net intangible assets	6,911	7,323
Trade Names [Member]
Gross intangible assets	4,700	4,700
Accumulated amortization	(353)	(224)
Net intangible assets	4,347	4,476
Developed Technology Rights [Member]
Gross intangible assets	2,880	2,880
Accumulated amortization	(432)	(281)
Net intangible assets	$ 2,448	$ 2,599

Note 10 - Goodwill and Intang_5

Note 10 - Goodwill and Intangible Assets - Estimated Future Amortization of intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
2024 (remaining nine months)	$ 2,004
2025	2,672
2026	2,672
2027	2,672
2028	1,571
Thereafter	2,115
Total	$ 13,706	$ 14,398

Note 11 - Accounts Payable an_3

Note 11 - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounts payable – trade	$ 12,752	$ 11,256
Accrued payroll and payroll taxes	356	167
Accrued PBM fees	366	571
Other accrued liabilities	81	164
Total	$ 13,555	$ 12,158

Note 12 - Notes Payable (Detail

Note 12 - Notes Payable (Details Textual) - USD ($)		1 Months Ended					3 Months Ended
	Dec. 31, 2018	Sep. 30, 2022	Jul. 31, 2022	Sep. 30, 2021	Apr. 30, 2021	Jan. 31, 2019	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Notes Payable, Current							$ 144,000		$ 145,000
Property, Plant and Equipment, Net							3,220,000		3,284,000
Interest Expense, Debt							16,000	$ 51,000
Mortgage Note Payable Commercial Bank Collateralized [Member]
Secured Debt	$ 1,530,000
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Repayments of Debt						$ 11,901
Note Payable Collateralized Pharmacy Equipment [Member]
Debt Instrument, Interest Rate, Stated Percentage				6.90%
Payments to Acquire Machinery and Equipment					$ 30,000
Debt Instrument, Periodic Payment				$ 331
Notes Payable, Current							5,000		6,000
Note Payable Collateralized [Member] | Pharmacy Equipment [Member]
Debt Instrument, Interest Rate, Stated Percentage			8.78%
Payments to Acquire Machinery and Equipment			$ 90,000
Notes Payable, Current							70,000		74,000
Property, Plant and Equipment, Net							68,000		71,000
Note Payable Collateralized [Member] | Pharmacy Equipment [Member] | Sixty Monthly Payments [Member]
Debt Instrument, Periodic Payment			$ 1,859
Note Payable Collateralized [Member] | Vehicles [Member]
Debt Instrument, Interest Rate, Stated Percentage		8.29%
Payments to Acquire Machinery and Equipment		$ 25,000
Debt Instrument, Periodic Payment		$ 1,143
Property, Plant and Equipment, Net							17,000		18,000
Notes Payable							$ 7,000		$ 10,000
Next Plat Investors [Member]
Debt Instrument, Maturity Date	Dec. 14, 2028

Note 12 - Notes Payable - Sched

Note 12 - Notes Payable - Schedule of Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Note payable	$ 1,225	$ 1,255
Less: current portion of notes payable	144	145
Long-term portion of notes payable	1,081	1,110
Mortgage Note Payable Commercial Bank Collateralized [Member]
Note payable	1,118	1,140
Note Payable Uncollateralized [Member]
Note payable	25	25
Note Payable Collateralized [Member]
Note payable	$ 82	$ 90

Note 12 - Notes Payable - Sch_2

Note 12 - Notes Payable - Schedule of Future Maturities (Details) $ in Thousands	Mar. 31, 2024 USD ($)
2024 (remaining nine months)	$ 115
2025	114
2026	119
2027	124
2028	753
Total	$ 1,225

Note 13 - Stockholders' Equity

Note 13 - Stockholders' Equity (Details Textual) - USD ($)			1 Months Ended
	Jul. 01, 2023	May 05, 2023	Aug. 31, 2022	Aug. 30, 2022	Jul. 31, 2014	Mar. 31, 2024	Dec. 31, 2023	Sep. 02, 2022
Preferred Stock, Shares Authorized (in shares)						10,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.0001	$ 0.0001
Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.2
Debenture Purchase Agreement, Term (Year)		3 years
Debenture Purchase Agreement, Maximum Debt to be Issued		$ 10,000,000
Secured Debt		$ 0
Debt Conversion Agreement [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 2.2
Debt Conversion, Original Debt, Amount		$ 2,900,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)		1,312,379
Debt Conversion Agreement [Member] | NextPlat Corp. [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		570,599
Debt Conversion Agreement [Member] | Chairman and Chief Executive Officer [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		228,240
Debt Conversion Agreement [Member] | Vice-Chairman of the Board of Directors [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		228,240
Amended and Restated Secured Convertible Promissory Note [Member]
Debt Instrument, Face Amount								$ 2,800,000
PIPE Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Warrants and Rights Outstanding		$ 1,000,000
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	230,056
Conversion Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Warrants and Rights Outstanding		$ 2,700,000					$ 600,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrants or Rights, Exercised (in shares)	230,000
Stock Issued During Period, Value, Warrants Exercised	$ 506,000
Stock Issued During Period, Shares, Cash Exercise of Warrants (in shares)	230,000
Conversion Warrants [Member] | NextPlat Corp. [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	172,213
Class of Warrants or Rights, Exercised, Cashless (in shares)	340,599
Conversion Warrants [Member] | Messrs. Fernandez and Barreto [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	115,402
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		5 years
Warrants and Rights Outstanding		$ 200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		91,000
Inducement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 2.2
Warrants and Rights Outstanding, Term (Year)		3 years
Warrants and Rights Outstanding		$ 700,000				$ 200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		330,000
Inducement Warrants [Member] | Chairman and Chief Executive Officer [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		190,000
Inducement Warrants [Member] | Vice-Chairman of the Board of Directors [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		30,000
Inducement Warrants [Member] | Messrs. Fernandez [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	96,068
Inducement Warrants [Member] | Barreto [Member]
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)	15,169
Securities Purchase Agreement [Member]
Proceeds From Issuance or Sale of Equity, Gross		$ 1,000,000
Equity Offering, Units Issued (in shares)		455,000
Equity Offering, Units Issued, Price Per Share (in dollars per share)		$ 2.2
Number of Shares Per Unit Issued (in shares)		1
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001
Number of Warrants Per Unit (in shares)		1
Proceeds from Issuance or Sale of Equity		$ 880,000
Payments of Stock Issuance Costs		70,000
Legal Fees		$ 50,000
Securities Purchase Agreement [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001
Sale of Stock, Number of Shares Issued in Transaction (in shares)				3,000
Proceeds from Issuance of Private Placement				$ 6,000,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)						51	51
Preferred Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.001	$ 0.001
Stock Issued During Period, Shares, New Issues (in shares)			51		51
Preferred Stock, Voting Percentage					50.99%
Amount for Exchange of Voting Power					$ 20,000
Stock Issued During Period, Shares, Acquisitions (in shares)			127,564
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)						100,000	100,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.0001	$ 0.0001
Undesignated Preferred Stock, Shares Authorized (in shares)						9,899,949	9,899,949
Undesignated Preferred Stock, Par Value (in dollars per share)						$ 0.0001	$ 0.0001
Preferred Stock, Liquidation Preference Per Share (in dollars per share)				$ 2,000
Series B Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 2,000
Preferred Stock Voting Rights Shares (in shares)				500
Debt Instrument, Convertible, Conversion Price (in dollars per share)				$ 4
Proceeds From Issuance or Sale of Equity, Gross				$ 1,000,000

Note 14 - Stock-based Compens_2

Note 14 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expense	$ 65,000	$ 60,000
Share-Based Payment Arrangement, Expense, Tax Benefit	$ 0

Note 15 - Reportable Segments_2

Note 15 - Reportable Segments (Details Textual)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)
Number of Reportable Segments	2
Payments to Acquire Property, Plant, and Equipment	$ 24,000	$ 17,000
Pharmacy Operations [Member]
Payments to Acquire Property, Plant, and Equipment	$ 100,000	$ 17,000

Note 15 - Reportable Segments -

Note 15 - Reportable Segments - Summary of Reportable Segments (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024		Mar. 31, 2023
Revenues, net		$ 14,628		$ 11,392
Costs of revenue		10,623		8,245
Gross profit		4,005		3,147
Salaries and wages		2,116		1,598
Professional fees		478		774
Depreciation and amortization		776		64
Selling, general, and administrative		900		697
Impairment loss		132	[1]	0
Total operating expenses		4,402		3,133
Income (loss) from operations		(397)		14
Other (expense) income		25		(144)
Income (loss) before income taxes		(372)		(130)
Provision for income taxes		0		0
Net loss		(372)		(130)
Intersegment Eliminations [Member]
Revenues, net		0		0
Costs of revenue		0		0
Gross profit		0		0
Salaries and wages		182		120
Professional fees		393		295
Depreciation and amortization		5		0
Selling, general, and administrative		123		105
Impairment loss	[1]	0
Total operating expenses		703		520
Income (loss) from operations		(703)		(520)
Other (expense) income		39		(132)
Income (loss) before income taxes		(664)		(652)
Provision for income taxes		0		0
Net loss		(664)		(652)
Product [Member]
Revenues, net		11,255		9,794
Costs of revenue		10,560		8,196
Product [Member] | Intersegment Eliminations [Member]
Revenues, net		0		0
Costs of revenue		0		0
Service [Member]
Revenues, net		3,373		1,598
Costs of revenue		63		49
Service [Member] | Intersegment Eliminations [Member]
Revenues, net		0		0
Costs of revenue		0		0
Pharmacy Operations [Member] | Operating Segments [Member]
Revenues, net		14,095		10,875
Costs of revenue		10,560		8,196
Gross profit		3,535		2,679
Salaries and wages		1,901		1,445
Professional fees		4		383
Depreciation and amortization		615		60
Selling, general, and administrative		770		588
Impairment loss	[1]	132
Total operating expenses		3,422		2,476
Income (loss) from operations		113		203
Other (expense) income		(14)		(13)
Income (loss) before income taxes		99		190
Provision for income taxes		0		0
Net loss		99		190
Pharmacy Operations [Member] | Product [Member] | Operating Segments [Member]
Revenues, net		11,255		9,794
Costs of revenue		10,560		8,196
Pharmacy Operations [Member] | Service [Member] | Operating Segments [Member]
Revenues, net		2,840		1,081
Costs of revenue		0		0
Third-party Administration [Member] | Operating Segments [Member]
Revenues, net		533		517
Costs of revenue		63		49
Gross profit		470		468
Salaries and wages		33		33
Professional fees		81		96
Depreciation and amortization		156		4
Selling, general, and administrative		7		4
Impairment loss	[1]	0
Total operating expenses		277		137
Income (loss) from operations		193		331
Other (expense) income		0		0
Income (loss) before income taxes		193		331
Provision for income taxes		0		0
Net loss		193		331
Third-party Administration [Member] | Product [Member] | Operating Segments [Member]
Revenues, net		0		0
Costs of revenue		0		0
Third-party Administration [Member] | Service [Member] | Operating Segments [Member]
Revenues, net		533		517
Costs of revenue		$ 63		$ 49
[1]Pharmacy Operations impairment losses during the three months ended March 31, 2024 was related to the write-down of a right-of-use asset as a result of taking the leased equipment out of service and not returning to service in the future.

Note 15 - Reportable Segments_3

Note 15 - Reportable Segments - Total Assets (Details) - USD ($) $ in Thousands		Mar. 31, 2024	Dec. 31, 2023
Total Assets		$ 41,398	$ 40,384
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Total Assets		0	69
Intersegment Eliminations [Member]
Total Assets	[1]	(2,774)	(2,774)
Pharmacy Operations [Member] | Operating Segments [Member]
Total Assets		39,439	38,516
Third-party Administration [Member] | Operating Segments [Member]
Total Assets		$ 4,733	$ 4,573
[1]Eliminations consist of investments in subsidiaries between the Pharmacy Operations segment and Corporate.

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual) - Management Services Agreement [Member] - NextPlat Corp. [Member] - USD ($)			3 Months Ended
	May 01, 2023	Feb. 01, 2023	Mar. 31, 2024	Mar. 31, 2023
Payment for Management Fee			$ 60,000
Management Fee Expense	$ 20,000	$ 25,000		$ 50,000